SGX Market Updates

Inflation & Slower Growth Outlook Fuels Further Selling in Global Stock Markets


20 June 2022

  • For the 2Q22 to date, the STI has generated an 8% decline in total return, with the FTSE Developed Index declining 16%. For the quarter, the broader Singapore stock market has seen S$1.05 billion of net institutional outflow, reducing the 2022 year-to-date net institutional inflow to S$74 million, with the STI 2022 year-to-date total return at 1%.

  • As global inflation gauges have continued to press longer term record levels since 31 March, expectations for the end of 2022 US Fed Funds Rate have increased from 225-250 bps to 350-375 bps. The impact of higher rates has also weighed global growth outlooks, with the World Bank tapering its 2022 global growth estimate to 2.9% (from 4.1%).

  • The technology sector has continued to weigh global stocks since 31 March, with hospitality & real estate also lagging, while the defensive outperformance of global banks seen in 1Q22 narrowed considerably. In Singapore, banks, technology and REITs have now booked the most net institutional outflows across the sectors in the 2022 year-to-date.

  • The 20 stocks among the most actively traded Singapore stocks that booked the highest net institutional inflows in the 2022 year-to-date proportionate to their current market capitalisation, included five REITs and five industrial stocks, with the remaining 10 stocks representing eight sectors. These 20 stocks averaged a 22% total return in the 2022 year-to-date.

For the 2Q22 through to 17 June, the STI has declined 9.1%, with the dividend distributions of May reducing the decline to 7.6% in total return terms. This is half the declines of the FTSE Developed Index, which has generated a 15.8% decline in total return over the same 11 weeks.

1Q22 vs 2Q22 STI and FTSE Developed Index Returns

The technology sector has continued to be the weakest of the global stock sectors in the 2Q22, as global inflation gauges have continued to revisit longer term record levels which has seen the majority of expectations for the end of 2022 US Fed Funds Rate (based on CME FedWatch) increase from 225-250 bps to 350-375 bps. The impact of the inflation and higher rates has also weighed global growth outlooks, with the World Bank this month reducing its 2022 global growth estimate to 2.9%, superseding a more optimistic outlook or 4.1% made in January.

Shifting of Fund Flows in 2022 Year-To-Date

  • Like 1Q22, the STI composition benefited from the comparative performances of banks over technology, with global technology stocks declining some 8% more than global bank stocks since 31 March. For 1Q22, the broader Singapore stock market attracted S$1.12 billion of net institutional inflows, and since 1Q22, has seen S$1.05 billion of net institutional outflows, resulting in 2022 year-to-date net institutional inflows of S$74 million, with the STI posting a marginal year-to-date total return of 1.2%.

  • Approximately half of the stocks traded on Singapore Exchange have booked net institutional inflows in the year-to-date, while half have booked net outflows. For passive investors however, there has been some rotation to the STI for the first 13 sessions of June with the two ETFs that track the STI on track to record their first monthly inflows for 2022, after five consecutive months of net outflows that exceeded S$100 million from January through to the end of May 2022.

Focusing on the 100 most traded SGX stocks by turnover this year, the 20 stocks that have booked the highest net institutional inflows, not on absolute basis, but proportionate to their current market capitalisation, have averaged 22% total returns in the year-to-date. As many as 19 of the stocks generated positive total returns, while one stock, Singapore Post (SGX:S08), remained unchanged.

The 20 stocks have also booked a total of S$1.94 billion of net institutional inflows in the year-to-date, led by SingTel (SGX:Z74). The 20 stocks are tabled below.

Actively Traded Singapore Stocks
with Highest YTD Net Institution
Inflows Proportionate to
Market Cap
YTD Institution
Net Inflow
YTD Institution
Net Inflow
as % of
Market Cap
YTD Total
QTD Total
Jiutian Chemical C8R 195 23 12.0% 40 22 Materials & Resources
Riverstone AP4 971 36 3.7% 7 -27 Healthcare
City Developments C09 7,382 243 3.3% 24 7 Real Estate (excl. REITs)
Sembcorp Industries U96 4,892 142 2.9% 38 4 Utilities
Keppel Corporation BN4 11,662 193 1.7% 32 5 Industrials
Samudera Shipping S56 407 6 1.5% 55 1 Industrials
Hong Fok H30 775 11 1.4% 24 9 Real Estate (excl. REITs)
SingTel Z74 40,791 524 1.3% 6 -6 Telecommunications
Sembcorp Marine S51 3,421 42 1.2% 33 11 Industrials
Ascott Residence Trust HMN 3,780 44 1.2% 14 2 REITs
SGX S68 10,327 119 1.1% 4 -4 Financial Services
Sheng Siong OV8 2,300 25 1.1% 7 3 Consumer Non-Cyclicals
Bumitama Agri P8Z 1,179 13 1.1% 31 -7 Consumer Non-Cyclicals
Suntec REIT T82U 4,851 53 1.1% 15 -2 REITs
CapitaLand Integrated Commercial Trust C38U 14,320 154 1.1% 6 -4 REITs
Jardine C&C C07 11,928 123 1.0% 51 24 Consumer Cyclicals
Frasers Hospitality Trust ACV 1,339 13 1.0% 51 31 REITs
Keppel REIT K71U 4,206 41 1.0% 3 -7 REITs
ST Engineering S63 12,218 118 1.0% 8 -2 Industrials
Singapore Post S08 1,462 12 0.8% 0 0 Industrials
Average 22 3
Total 138,406 1,935

Source: SGX, Bloomberg, Refinitiv (Data as of 17 June 2022)

As shown in the table above, Jiutian Chemical (SGX:C8R) has booked S$23 million of net institutional inflow in the year-to-date which represents 12.0% of the stock’s current market capitalisation of S$195 million. Representing the Materials & Resources sector, Catalist-listed and Henan-based company manufactures and produces dimethylformamide (“DMF”), methylamine, sodium hydrosulfate and dimethylacetamide.

For its 1Q22, Jiutian Chemical reported net profit of RMB 201 million, a 123% increase over the same period last year, notwithstanding 15 days of lower production volume in January 2022 due to COVID related restriction affecting logistics. This followed on from its 2021 net profit growing 87% from 2020, on increased demand for its products by downstream users as well as surge in average selling prices of DMF and Methylamine. Since the end of 2019, Jiutian Chemical Group’s market capitalisation has grown 6-fold from just over S$30 million to over S$190 million.

See also: SGX market fund flow summary.

This article is provided by SGX My Gateway.

SGX My Gateway

SGX's investor education portal with market, product and investment information and events. Sign up now at to receive our investment updates and economic calendar.

This document is not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject Singapore Exchange Limited (“SGX”) to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document is for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Use of and/or reliance on this document is entirely at the reader’s own risk. Further information on this investment product may be obtained from Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. Examples provided are for illustrative purposes only. While each of SGX and its affiliates (collectively, the SGX Group Companies) have taken reasonable care to ensure the accuracy and completeness of the information provided, each of the SGX Group Companies disclaims any and all guarantees, representations and warranties, expressed or implied, in relation to this document and shall not be responsible or liable (whether under contract, tort (including negligence) or otherwise) for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind, including without limitation loss of profit, loss of reputation and loss of opportunity) suffered or incurred by any person due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information, or arising from and/or in connection with this document. The information in this document may have been obtained via third party sources and which have not been independently verified by any SGX Group Company. No SGX Group Company endorses or shall be liable for the content of information provided by third parties. The SGX Group Companies may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore. The information in this document is subject to change without notice. This document shall not be reproduced, republished, uploaded, linked, posted, transmitted, adapted, copied, translated, modified, edited or otherwise displayed or distributed in any manner without SGX’s prior written consent.

Stock / REIT Search